{"id":"pyridoxine-plus-prednisolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Peripheral neuropathy (pyridoxine at high doses)"}]},"_chembl":{"chemblId":"CHEMBL1364","moleculeType":"Small molecule","molecularWeight":"169.18"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pyridoxine is an essential cofactor for numerous enzymatic reactions involved in immune cell function and neurotransmitter synthesis. Prednisolone is a corticosteroid that binds glucocorticoid receptors to reduce inflammation, suppress immune cell proliferation, and decrease production of pro-inflammatory cytokines. The combination likely aims to provide nutritional support while managing inflammatory or autoimmune conditions.","oneSentence":"Pyridoxine (vitamin B6) supports immune function and nervous system health while prednisolone suppresses inflammatory and immune responses through glucocorticoid receptor activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:30:49.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune or inflammatory conditions (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT06446245","phase":"PHASE2","title":"Adjunctive Doxycycline for Central Nervous System Tuberculosis","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-08-21","conditions":"Tuberculosis, Meningeal, Tuberculosis; Meningitis (Etiology), Tuberculosis, Central Nervous System","enrollment":200},{"nctId":"NCT05638633","phase":"PHASE3","title":"Prednisolone and Vitamin B1/6/12 in Patients With Post-Covid-Syndrome","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2022-11-11","conditions":"Post-COVID-19 Syndrome","enrollment":321},{"nctId":"NCT01828437","phase":"PHASE3","title":"Addition of Pyridoxine to Prednisolone in Infantile Spasms","status":"COMPLETED","sponsor":"Lady Hardinge Medical College","startDate":"2012-11","conditions":"Infantile Spasms","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pyridoxine plus prednisolone","genericName":"Pyridoxine plus prednisolone","companyName":"Lady Hardinge Medical College","companyId":"lady-hardinge-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pyridoxine (vitamin B6) supports immune function and nervous system health while prednisolone suppresses inflammatory and immune responses through glucocorticoid receptor activation. Used for Autoimmune or inflammatory conditions (specific indication not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}